T he discipline of critical care pharmacy practice has evolved over the past 25 yrs to become an essential component of the multidisciplinary team in the intensive care unit (ICU) (1) (2) (3) . In the early 1970s, there were a few practitioners practicing in critical care as members of surgical or trauma services and cardiac arrest teams. Over the next decade, pharmacy services expanded to various ICU settings (both adult and pediatric), the operating room, and the emergency department. In these settings, pharmacists established clinical practices consisting of therapeutic drug monitoring, nutrition support, and participation in patient care rounds. Pharmacists also established efficient and safe drug delivery systems with the evolution of critical care pharmacy satellites and other innovative programs. In the 1980s, critical care pharmacists initiated specialized training programs and increased their participation in critical care organizations. The number of critical care residencies and fellowships doubled between the early 1980s and the late 1990s. Standards for a critical care residency were developed (4) and currently directories of residencies and fellowships are published (5, 6) . Several professional pharmacy organizations have specialty groups consisting of critical care pharmacists. These include the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, and the Operating Room Satellite Pharmacy Association. In 1989, the Clinical Pharmacy and Pharmacology Section was formed within the Society of Critical Care Medicine, the largest international, multidisciplinary, multispecialty critical care organization.
This recognition acknowledged that pharmacists are necessary and valuable members of the physician-led multidisciplinary team.
The Society of Critical Care Medicine Guidelines for Critical Care Services and Personnel deem the pharmacists are essential for the delivery of quality care to critically ill patients. These Guidelines recommend that a pharmacist monitor drug regimens for dosing, adverse reactions, drug-drug interactions, and cost optimization for all hospitals providing critical care services (1) . The Guidelines for Critical Care Service and Personnel further recommend that a specialized, decentralized pharmacist provide expertise in nutritional support, cardiorespiratory resuscitation, and clinical research in academic medical centers providing comprehensive critical care (1) .
Objective: The goal of the Task Force on Critical Care Pharmacy Services was to identify and describe the scope of practice that characterizes the critical care pharmacist and critical care pharmacy services. Specifically, the aims were to define the level of clinical practice and specialized skills characterizing the critical care pharmacist as clinician, educator, researcher, and manager; and to recommend fundamental, desirable, and optimal pharmacy services and personnel requirements for the provision of pharmaceutical care to critically ill patients. Hospitals having comprehensive resources as well as those with more limited resources were considered. Data Sources: Consensus opinion of critical care pharmacists from institutions of various sizes providing critical care services within several types of pharmacy practice models was obtained, including community-based and academic practice settings. Ex-isting guidelines and literature describing pharmacy practice and medication use processes were reviewed and adapted for the critical care setting.
Conclusions: By combining the strengths and expertise of critical care pharmacy specialists with existing supporting literature, these recommendations define the level of clinical practice and specialized skills that characterize the critical care pharmacist as clinician, educator, researcher, and manager. This Position Paper recommends fundamental, desirable, and optimal pharmacy services as well as personnel requirements for the provision of pharmaceutical care to critically ill patients. In the last 10 yrs, clinical pharmacy has become increasingly specialized, and has developed specialty board certification (7) . The growth of critical care pharmacy practice as a specialty has paralleled this development. As a result, the pharmacist has increasingly assumed responsibility for patient outcomes in addition to supervising drug distribution services (3) .
Pharmacists have demonstrated a role in the management of drug costs and reductions in morbidity and mortality (2, 3, 6 -19) . Clinical pharmacy services such as clinical research, provision of drug information, drug admission histories, and participation on a CPR team have been associated with reduced mortality (11) . Prospective, controlled trials demonstrate that when pharmacists assume responsibility for pharmacotherapy as part of a multidisciplinary healthcare team, significant reductions in adverse drug events (ADEs) and length of stay are realized (12) (13) (14) (15) (16) . Many of these findings have been documented in specialized critical care populations (14 -20) . The American College of Clinical Pharmacy estimates that a benefit of $16.70 is realized for every $1.00 invested in clinical pharmacy programs (17) . A landmark study involving critical care pharmacists confirmed that pharmacist rounding in the ICU with the multidisciplinary team reduces preventable ADEs and associated costs caused primarily by prescribing errors (16) . Pharmacist intervention during prescribing decreased the rate of preventable ADEs by 66% from 10.4 to 3.5 per 1,000 patient-days (p Ͻ .001). Pharmacist recommendations were categorized as medication order clarification (45%), provision of drug information (25%), and recommendations of alternative therapy (12%). Based on an estimated cost of $4,685 per preventable ADE, the annualized financial impact in the unit studied would be $270,000 (in 1995 dollars).
Despite the growing evidence supporting the critical care pharmacists' contribution to patient care, many ICUs have not taken full advantage of this vital resource (18) . A description of pharmacy services and pharmacist activities in a critical care setting will assist practitioners and administrators in establishing or advancing these specialized pharmacy services. This Position Paper may be used to educate other health care providers, administrators and developers of health care policy regarding the role of pharmacists and pharmacy services in the care of the critically ill. Furthermore, the application of the elements in this Position Paper will allow researchers to further document the effect of critical care pharmacy services on improving patient outcomes.
Purpose
The purpose of this Position Paper is to identify and describe the scope of pharmacy practice of the critical care pharmacist and critical care pharmacy services. Specifically, the aims of the Task Force on Critical Care Pharmacy Services were as follows:
To define the level of clinical practice
and specialized skills characterizing the critical care pharmacist as clinician, educator, researcher and manager. 2. To recommend levels of service and personnel requirements for the provision of pharmaceutical care to critically ill patients. The levels were defined as fundamental, desirable, or optimal.
METHODS
The Task Force on Critical Care Pharmacy Services consisted of members from the Clinical Pharmacy and Pharmacology Section of the Society of Critical Care Medicine and the Critical Care Practice and Research Network of the American College of Clinical Pharmacy. Members of the Task Force were from institutions of various sizes and provide critical care services within a variety of pharmacy practice models. Practitioners from both communitybased and academic practice settings were included.
The formulation of these recommendations, including discussion and development of consensus, took place between October, 1997 and September, 1999. Task Force members were charged with the development of graded parameters within six domains: clinical activities, drug distribution, education, research, documentation, and administration. The Position Paper was organized into pharmacist activities and pharmacy services. Drafts were reviewed and evaluated by all members of the Task Force and a consensus was reached. When differences in opinion were expressed, they were resolved using a modified Delphi method (21) . The document was externally reviewed by three established leaders in critical care pharmacy, and by 18 pharmacy and hospital administrators for appropriateness of categorization of pharmacist activities and pharmacy services. This Position Paper was further reviewed by selected members and the Existing guidelines and literature for pharmacy practice and medication use processes were reviewed and adapted for the critical care setting (7, (22) (23) (24) . The needs of hospitals with comprehensive resources as well as those with more limited resources were considered. The Task Force created three gradations of pharmacist responsibilities and departmental services as fundamental, desirable, and optimal. Classification of the elements into each category was the result of the consensus process. For the purposes of this document, the following definitions are used. Fundamental activities are those recommended as vital to the safe provision of pharmaceutical care to the critically ill patient. Desirable activities include fundamental activities, and in addition, are more specialized and critical care specific pharmacotherapeutic services. Optimal activities encompass the range of fundamental to desirable services and, additionally, reflect an integrated, specialized and dedicated model of critical care which aims to optimize pharmacotherapeutic outcomes through the highest level of teaching, research, and pharmacotherapy practice. Fundamental services should not be interpreted as an acceptable minimum level of service. Each institution and practitioner should continually strive for the highest level of service possible.
A single pharmacist cannot perform all of the fundamental activities on all patients every day. Rather, these critical care pharmacy activities will require varying levels of involvement from multiple pharmacists and trained technicians acting as a team, along with support from pharmacy and hospital administrators, and other personnel. The exact allocation of labor and pharmacist-to-patient ratio will vary by institution and depend on the level of care, the acuity of patients, and the degree of specialization of the institution.
"The pharmacist," as used herein, refers to the team of licensed pharmacy practitioners with specialized training or practice experience focusing on the unique characteristics and needs of the critically ill patient. Although various practice models exist, the pharmacist practices within the framework of a multidisciplinary team. In collaboration with other members of the patient care team, pharmacists share the responsibility for patient care outcomes, not just by providing basic dispensing functions and drug information services, but by solving patient-and medication-related problems and by making decisions regarding drug prescribing, monitoring, and drug regimen adjustments (25) . The pharmacist's practice may integrate varying elements of patient care, teaching, and research activities, depending on the nature of the institution and the pharmacist's training.
The Task Force recognizes the varied educational backgrounds of practicing critical care pharmacists. Having the qualifications and competence necessary to provide pharmaceutical care in the ICU is essential and may be achieved by a variety of means including advanced degrees, residencies, fellowships or other specialized practice experience.
The term "Pharmacy and Hospital Services" refers to departmental and institutional/ organizational components of the infrastructure which support the pharmacists' activities. They consist of systems, operations, and personnel who facilitate and support provision of patient care, teaching, and research to optimize safe and effective pharmaceutical care of the critically ill.
This document is not intended to be a standard of practice; however we envision that it will serve as a guideline for hospitals of varying resources to optimize the delivery of pharmaceutical care to the critically ill. It is expected that these recommendations will continue to be reviewed at intervals of ϳ5 yrs as critical care pharmacy services, clinical pharmacy and critical care medicine all evolve.
Critical Care Pharmacist Activities
Fundamental Activities 1. The pharmacist's time is dedicated to critical care patients, with few commitments outside the ICU area. 2. The pharmacist prospectively evaluates all drug therapy for appropriate indication, dose, drug interactions, drug allergies, and monitors the patient's pharmacotherapeutic regimen for effectiveness and ADEs, and intervenes as needed. 3. In conjunction with the clinical dietitian, the pharmacist evaluates all orders for parenteral nutrition and recommends modifications as indicated to optimize the nutritional regimen. 4. The pharmacist identifies and assists in the management and prevention of ADE; the pharmacist develops process improvements to reduce medication errors and preventable ADEs. 5. The pharmacist utilizes the medical record as one means to communicate with other healthcare professionals, and to document specific pharmacotherapeutic recommendations.
6. The pharmacist provides pharmacokinetic monitoring when a targeted drug is prescribed. 7. The pharmacist provides drug information and intravenous compatibility information to the ICU team and utilizes the regional poison information center when indicated. 8 . The pharmacist maintains current tertiary drug references. 9. The pharmacist provides drug therapyrelated education to ICU team members. 10 prioritizing, and promoting new pharmacy programs and services. 10. The pharmacist secures funds for conducting research. 11. The pharmacist reports results of clinical research and pharmacoeconomic analyses to the pharmacy and medical community at regional and national meetings. 12. The pharmacist publishes in peerreviewed pharmacy and medical literature as a result of any of the following activities: a. Clinical research or other original research that qualitatively and quantitatively evaluates drug therapy and the provision of pharmacy service b. Investigator-initiated grants and contracts c. Pharmaeconomic and outcomes research
Pharmacy and Hospital Services
Fundamental Services 1. Medication use systems have the ability to: a. create and maintain patient medication profiles. b. interface with patient laboratory data. c. alert users to drug allergies. d. alert users to maximum dose limits. e. alert users to drug-drug and drug-food/ nutrient interactions. 2. If manual medication administration records are the only available medication administration record document, quality assurance systems are in place to verify the accuracy of this process.
3.
A "ready to administer" (unit-dose) drug distribution system is available in the ICU with no more than a 24-hr supply for each patient. 4. Large-and small-volume parenteral products are prepared in the pharmacy and delivered at regularly scheduled time intervals to the patient care area 7 days/wk. 5. Pharmacy space and facilities in the ICU are regularly assessed to determine whether efficiency can be improved, where applicable. 6. Procurement, storage, inventory, and distribution of investigational drugs, where applicable, are under the supervision of a pharmacist. 7. The pharmacy department is represented on the Institutional Review Board and/or Scientific Review Board, as applicable.
